226 related articles for article (PubMed ID: 24293465)
1. New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension.
Preston IR; Suissa S; Humbert M
Eur Respir Rev; 2013 Dec; 22(130):495-502. PubMed ID: 24293465
[TBL] [Abstract][Full Text] [Related]
2. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
Gaine S; Simonneau G
Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
Studer SM; Gilkin RJ
Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
[TBL] [Abstract][Full Text] [Related]
4. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
Fritz JS; Blair C; Oudiz RJ; Dufton C; Olschewski H; Despain D; Gillies H; Kawut SM
Chest; 2013 Feb; 143(2):315-323. PubMed ID: 22814814
[TBL] [Abstract][Full Text] [Related]
5. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
Kylhammar D; Persson L; Hesselstrand R; Rådegran G
Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
[TBL] [Abstract][Full Text] [Related]
6. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.
Frost AE; Badesch DB; Miller DP; Benza RL; Meltzer LA; McGoon MD
Chest; 2013 Nov; 144(5):1521-1529. PubMed ID: 23907471
[TBL] [Abstract][Full Text] [Related]
8. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
[TBL] [Abstract][Full Text] [Related]
9. Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.
Sun H; Stockbridge N; Ariagno RL; Murphy D; Nelson RM; Rodriguez W
J Perinatol; 2016 Dec; 36(12):1029-1033. PubMed ID: 27416322
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
Trials; 2013 Apr; 14():91. PubMed ID: 23547564
[TBL] [Abstract][Full Text] [Related]
11. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective.
Gomberg-Maitland M; Dufton C; Oudiz RJ; Benza RL
J Am Coll Cardiol; 2011 Mar; 57(9):1053-61. PubMed ID: 21349396
[TBL] [Abstract][Full Text] [Related]
12. A paradigm shift in pulmonary arterial hypertension management.
Rubin LJ; Galiè N; Simonneau G; McLaughlin V
Eur Respir Rev; 2013 Dec; 22(130):423-6. PubMed ID: 24293459
[No Abstract] [Full Text] [Related]
13. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
[TBL] [Abstract][Full Text] [Related]
15. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
Sitbon O; Vonk Noordegraaf A
Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
[TBL] [Abstract][Full Text] [Related]
16. Exercise as an end-point in pulmonary hypertension trials.
McCullagh B; Girgis RE
Int J Clin Pract Suppl; 2010 Jan; (165):4-6. PubMed ID: 19958394
[TBL] [Abstract][Full Text] [Related]
17. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary arterial hypertension: a review in pharmacotherapy.
Patel BB; Feng Y; Cheng-Lai A
Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.
Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M
Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844
[TBL] [Abstract][Full Text] [Related]
20. Looking to the future: a new decade of pulmonary arterial hypertension therapy.
McLaughlin VV
Eur Respir Rev; 2011 Dec; 20(122):262-9. PubMed ID: 22130819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
